Prescription drug · ANDA
Calcitriol NDC 0054-0007
Calcitriol .25 ug/1 · Capsule · Oral · Hikma Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0054-0007-13 | 00054000713 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0054-0007-13)Marketed from Mar 27, 2006 | |
| 0054-0007-25 | 00054000725 | 100 CAPSULE in 1 BOTTLE, PLASTIC (0054-0007-25)Marketed from Mar 27, 2006 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Calcitriol
- Generic name (nonproprietary)
- calcitriol
- Active ingredients
- Calcitriol — .25 ug/1
- Dosage form
- Capsule
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 076917
- Marketing start
- Listing expires
- Other FDA classes
- Cholecalciferol (Chemical structure)
- Identifiers
- Product ID 0054-0007_81dbfa92-024a-48d1-94de-84e3394f043cSPL ID 81dbfa92-024a-48d1-94de-84e3394f043cSPL set ID cdcaffc6-e14e-4607-b77b-fc78a8382f60RxCUI 308867UNII FXC9231JVHUPC 0300540007133
- Pharmacologic class
- Vitamin D3 Analog
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400054000713followed by a unit qualifier and the quantityPackage 00054-0007-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces seru…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 076917
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Calcitriol | Calcitriol .25 ug/1 | CapsuleOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-521 |
| Calcitriol | Calcitriol .25 ug/1 | CapsuleOral | PD-Rx Pharmaceuticals, Inc. | 72789-058 |